

07

KEY TAKEAWAYS

Carlo Rosa

CEO

Looking Forward to 2030: what do we commit to deliver

Immunodiagnosics

>20 new assays to cover
Autoimmunity, GI and ID specialties

New LIAISON XL with enhanced
features for high-throughput
customers

Leverage on automation and
competitive advantage in TB market
to maintain market leadership

Launch of 1 Companion Diagnostic
product

Molecular Diagnostics

Increasing competitiveness of LIAISON
NES, expanding in women's health

Complete the LIAISON PLEX table
stake panels, adding
Meningitis/Encephalitis on top of the
existing RSP, Blood and GI panels

Launch of a new generation platform,
LIAISON MDX Plus, supporting our
specialty portfolio

Licensed Technologies

Increasing revenue opportunity through
new contracts with Diagnostic and
Biopharma partners

Stabilization of sales to customers
linked to Academia

Leveraging proprietary technology to
drive scalable licensing, royalties and
long-term recurring revenue streams

Leveraging automation and AI in Operations to expand margins

Commercial geographical expansion in key countries

Optimizing R&D spending and installed base investments



Diasorin